TMS in Inflammatory Bowel Disease
Evaluating the Antidepressant Efficacy of Transcranial Magnetic Stimulation (TMS) in Patients With Inflammatory Bowel Disease (IBD) and Effects on IBD-related Symptoms.
Sponsor: IMAGINE (Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects)
Terminated
poor recruitment
Other Inflammatory Bowel Diseases trials with similar outcome
This PHASE2 trial investigates Inflammatory Bowel Diseases and Maladaptive Behavior Associated With Physical Illness and is currently terminated or withdrawn. IMAGINE (Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects) leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2022 — May 2023 [monthly]
Recruiting PHASE2
-
Sep 2021 — Jan 2022 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- IMAGINE (Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects)
- University of Calgary
For direct contact, visit the study record on ClinicalTrials.gov .